News Details - novonordisk.com
1 day ago · About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is developed for oral and subcutaneous administration.
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin …
14 hours ago · Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% ...
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight …
13 hours ago · On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...
Novo Nordisk successfully completes phase 1b/2a trial with
14 hours ago · About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is developed for oral and subcutaneous administration.
Novo Nordisk's next-gen obesity treatment hits target in early …
13 hours ago · Novo said that patients on a high dose of the injectable form of the drug, called amycretin, lost 22% of their weight after 36 weeks, when analyzing the effects if all people adhered to treatment.
Novo Nordisk shares jump on fresh trial results - Financial Times
13 hours ago · People treated with amycretin lost up to 22 per cent of their body weight after 36 weeks. ... Shares in Novo Nordisk, one of Europe’s most valuable companies, jumped 8 per cent on Friday after ...
Weight loss: Amycretin pill may be more effective than semaglutide
Sep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have developed to treat obesity...
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
2 days ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.
Amycretin - Wikipedia
Amycretin is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally.
Experimental Oral Drug Shows 'Remarkable' Weight Loss, Novo Nordisk …
Sep 23, 2024 · In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second hormone called amylin. Amylin appears to act in the brain, rather than in the gut.
- Some results have been removed